10:42:42 EDT Wed 19 Jun 2019
Enter Symbol
or Name

Login ID:

News for U:NVO from 2018-06-20 to 2019-06-19 - 12 items News ReleasesIn The NewsOther
2019-04-30 12:15NVONews ReleaseRenewable electricity to completely power Novo Nordisk US operations in early 2020
2019-03-01 07:00NVONews ReleaseNovo Nordisk files for a label update for Fiasp ® to the EMA and the FDA seeking approval for use in children and adolescents
2019-02-11 07:30NVONews ReleaseMarket Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings
2019-01-23 08:00NVONews ReleaseXultophy ® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes
2018-10-26 08:45NVONews ReleaseInvestor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence
2018-10-01 08:00NVONews ReleaseHealth Canada approves TRESIBA ® for children with Type 1 diabetes
2018-09-26 08:00NVONews ReleaseResearch Report Identifies EnLink Midstream Partners, LP, Methanex, Novo Nordisk A/S, Magellan Midstream Partners, Arch Capital Group, and KT with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
2018-09-21 08:12NVONews ReleaseOntario becomes first province to provide public funding of TRESIBA ® for adults with diabetes mellitus
2018-09-12 06:00NVONews ReleaseEyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
2018-09-10 07:00NVONews ReleaseEyePoint Pharmaceuticals Elects G ¶ran Ando, M.D. as Next Chairman of Board of Directors
2018-06-26 07:00NVONews ReleaseEyePoint Pharmaceuticals Appoints G ¶ran Ando, M.D., to Board of Directors
2018-06-23 10:00NVONews ReleaseTresiba ® demonstrated significantly improved blood sugar control and lower rates of hypoglycemia versus insulin Toujeo ® in real-world evidence study